Simplicity is a virtue.

• The House of Representatives and the Senate remain in session on Capitol Hill this week for Committee business and floor voting.

• Per a House Energy and Commerce Committee news release,
  • “The Subcommittee on Health has scheduled a hearing on Wednesday, June 10, 2026, at 10:15 a.m. (ET) in 2123 Rayburn House Office Building. The title of the hearing is “Lowering Health Care Costs for All Americans: Examining Policies to Increase Health Care Transparency.”

• HR Dive reports,
  • “A hospital may employ staff as overtime-exempt specialists who simultaneously take shifts performing nonexempt staff nurse work during the same workweek without altering the employees’ exemption status under the Fair Labor Standards Act, the U.S. Department of Labor said in an opinion letter issued Thursday.
  • “The document is one of a group of four letters issued last week by DOL Wage and Hour Division Administrator Andrew Rogers. Rogers said the FLSA’s executive, administrative and professional overtime exemption applies to employees whose “primary duty” involves performance of exempt work.”

From the public health and medical / Rx research front.

• The Wall Street Journal reports,
  • “The federal government reported America’s total fertility rate dropped to 1.57, sparking alarm about a graying, shrinking population.
  • “Experts note the 1.57 total fertility rate is a snapshot, with 30% of the decline from falling teen pregnancy rates.
  • “Medical solutions like IVF and egg freezing, along with policies for workplace flexibility and childcare, are discussed to address declining fertility.”
• and
  • “Cancer rates are rising among people under 50, an alarming trend that has led some patients to take preventive measures. While women under 45 make up a small number of overall breast cancer cases, incident rates have increased 1.1% each year for the past 10 years. 
  • “Armed with more information than ever about their genetics, women with higher risk factors are opting for surgeries that reduce their odds of developing cancer by as much as 95%. Doctors specializing in breast reconstruction say they are seeing ever-younger women opting to remove their breasts as a prophylactic measure. 
  • “At this point, seeing a patient in their early 30s is totally routine,” said Dr. Steven Sultan, a plastic and reconstructive surgeon at New York City’s Mount Sinai Hospital, referring to cancer patients. He said about 20% of his cases are prophylactic, a term that encompasses women who take action as soon as they learn about genetic risk factors and those who have undergone biopsies after suspicious scans but do not have cancer. In the past few years, he’s seen a notable change in 20-somethings coming into his office, both with cancer as well as for prophylactic surgeries.” 

• The New York Times relates,
  • “Scientists at Columbia University have edited the DNA of early human embryos with unprecedented accuracy, an achievement that could open the way to babies engineered with particular characteristics.
  • “The prospect has fueled controversy for years. On the one hand, the technology might one day enable parents to safely repair disease-causing mutations in embryos. But it might also be used to select desired traits — a practice that some ethicists have argued is nothing short of eugenics.
  • “Dieter Egli, a geneticist at Columbia University who led the research, called for a public conversation about the pros and cons of altering embryonic DNA. “As a scientist, you can provide the data for discussion, but then essentially there you stop and let others take over,” he said.
  • “With a newer technology called base editing, Dr. Egli and his colleagues were able to meticulously replace individual genetic letters in sequences of DNA without causing the damage often observed with an earlier form of gene editing, CRISPR.
  • “Dr. Egli cautioned that the research left unanswered many questions about harmful side effects. “We’re not saying this is going to be used tomorrow in the clinics,” he said.
  • “Dr. Egli and his colleagues posted their study online. The research is under review for publication in a scientific journal.”

• Medscape tells us,
  • “Metabolic disruptions in individuals with alcohol use disorder (AUD) and obesity may intensify alcohol cravings, suggesting a potential metabolic-addictive axis. This highlights the need for integrated treatment approaches targeting both metabolic and addiction pathways.” * * *
  • “Lead author Zachary Harvanek, MD, PhD, assistant professor of medicine at Yale School of Medicine, New Haven, Connecticut, cautioned that the findings are preliminary and require confirmation in larger studies before they can influence clinical practice. However, he said the results suggest that metabolic health may play a meaningful role in alcohol cravings and could help identify a distinct subgroup of patients with AUD at an especially high risk for relaThe findings also support growing interest in therapies that target metabolic pathways, including GLP-1s, as potential treatments for AUD in certain patients.
• and
  • “Behavioral economics may enhance obesity management by improving adherence to lifestyle changes through financial incentives, gamification, and digital nudges. These strategies could complement pharmacologic treatments, though their long-term effectiveness remains uncertain.” * * *
  • “We all know that many patients regain weight after stopping GLP-1 medications — often a large proportion of what they lost within a year,” said Thomas Tsang, MD, chief medical officer at Omada Health. “In many cases, it’s because patients never had the opportunity to learn the behavioral skills and lifestyle tools needed to sustain those changes after the medication is stopped.”
  • “Tsang also expressed caution about programs that rely primarily on financial incentives. “If the incentive is purely financial, the concern is whether the behavior change will last after the incentive disappears,” he said. “What matters more is helping people develop durable habits and confidence that they can sustain over time.” * * *
  • Tsang also raised ethical concerns about programs that rely heavily on financial incentives, particularly if they disproportionately target economically vulnerable populations.
  • “There’s a fine line between rewarding progress and essentially paying people to lose weight,” he said. “We want patients focused on health and sustainable behavior change, not just achieving a short-term goal for a financial reward.”
  • “For now, most experts view behavioral-economics interventions as promising but still evolving tools.
  • “As the obesity treatment landscape expands — particularly with the rapid adoption of new pharmacologic therapies — understanding how behavioral design can support long-term adherence may become an increasingly important area of research.”
    
• STAT New informs us,
  • “Detailed data from a mid-stage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly. But it’s not clear how competitive the treatment would be against weekly injectables on the market and in development that may lead to greater weight loss.
  • “In the study, called VESPER-3, patients with obesity took weekly doses of the drug, called berobenatide, for 12 weeks and then transitioned to higher monthly doses out to 28 weeks. By then, patients lost up to 12.1% of their weight, when analyzing just those who stayed on treatment, as Pfizer previously reported. 
  • “New data presented at the annual meeting of the American Diabetes Association on Saturday show that when patients transitioned from weekly to monthly dosing, the rate of weight loss continued at a similar pace; they had not yet hit a plateau by 28 weeks. That’s a promising sign, but the rate of weight loss at 28 weeks was still less than what was seen at a similar time point in the pivotal trial of Eli Lilly’s Zepbound.
  • “Additionally, up to 11.3% of treated patients discontinued because of side effects, compared with none in the placebo group. When patients in the highest-dose groups transitioned from a weekly dose of 1.2 milligrams to monthly doses that were four times as large (4.8 mg), they experienced a notable increase in nausea and vomiting, the new data show.
  • “To help improve tolerability, Pfizer will titrate the monthly doses going forward rather than put patients on the 4.8-milligram dose right away, said Jim List, the company’s chief internal medicine officer.”

• Healio points out,
  • “A triple receptor agonist provided weight loss for adults with obesity, with or without type 2 diabetes, to an extent not seen with previous pharmacotherapy options, according to data from two phase 3 trials.
  • “During a symposium at the American Diabetes Association Scientific Sessions, researchers presented data from phase 3 trials investigating retatrutide (Eli Lilly), a once-weekly injectable GLP-1/GIP/glucagon triple hormone agonist. In the TRIUMPH-1 trial, the medication led to weight loss of up to 25% at 80 weeks and up to 29.9% at 104 weeks with the highest dose, as well as other benefits. 
  • “Retatrutide … was generally well tolerated, and provided substantial reduction in weight, as well as clinically meaningful improvements in health outcomes for patients with obesity, obstructive sleep apnea and knee osteoarthritis,” Ania M. Jastreboff, MD, PhD,director of the Yale Obesity Research Center and principal investigator of the TRIUMPH-1 trial, said in a press conference.
  • “In the TRANSCEND-T2D-1 trial, which was simultaneously published in The Lancet, HbA1c declined by 1.9 percentage points at 40 weeks for adults with type 2 diabetes with the two highest doses of the drug. Additionally, mean weight loss with the highest dose of retatrutide reached 12.7% at 40 weeks.”

• MedPage Today let us know,
  • “Two investigational drugs for lupus with encouraging primary phase II results yielded more good news from follow-on studies, reports here indicated.
  • “The Toll-like receptor (TLR) inhibitor enpatoran showed no diminution and perhaps some increase in efficacy for patients with cutaneous and systemic lupus with 48 weeks of additional treatment beyond the original 24 weeks, and no new safety concerns arose, according to Eric Morand, MBBS, PhD, of Monash University in Melbourne, Australia.
  • “The other study involved the anti-B cell agent ianalumab that is being tested in systemic lupus (and a variety of other conditions). Edward Vital, MBChB, PhD, of the University of Leeds in England, reported data collected after treatment had stopped in a phase II trial and after B-cell populations had rebounded. With a median of 44 weeks of post-treatment follow-up, not only did biomarker responses continue unabated, clinical indices also showed little loss of efficacy.” * * *
  • For both drugs, the phase II results were strong enough that their respective sponsors have initiated twinned phase III trials: ELOWEN-1and ELOWEN-2 for enpatoran, and SIRIUS-SLE-1 and SIRIUS-SLE-2 for ianalumab.
    

From the U.S. healthcare business report,

• MedCity News reports about “The Smart Way to Build the Future of Fertility Benefits.
  • “The challenge isn’t just access to fertility benefits, it’s how those benefits are structured and delivered. Here are three emerging themes that can help employers better align cost, quality and experience.” * * *
  • “First, look “under the hood” when evaluating healthcare options. Don’t just look at the price tag; compare the outcomes. High-quality medical care saves money in the long run and leads to better results. Accurate diagnostics, advanced lab practices, and evidence-based protocols increase the likelihood of pregnancy and reduce the number of failed IVF cycles – saving time, money, and emotional strain for employees. 
  • “Second, prioritize collaboration, not fragmentation. Fertility care works best when clinicians, labs, and pharmacies operate in a more coordinated way. Collaboration enables faster, better-informed decisions, reduces referrals, and shortens the time to pregnancy. It also lowers costs by avoiding redundant testing and treatment. For employees, integrated care means less logistical stress and more confidence in the process. 
  • “Third, demand transparency in drug pricing. IVF medications can be one of the most opaque and wasteful parts of the process. Typically, patients receive their rebates at the end of the year, if at all, while leftover drugs go unused. More transparent approaches, including upfront drug pricing, same-day delivery, and as-needed dispensing, reduces waste and helps employees with financial planning.” 

• The Wall Street Journal relates,
  • “Coverage for Ozempic and other drugs used for weight loss has fast become one of the most coveted workplace benefits—so much so that companies say they can no longer afford to provide it.
  • “With as many as one in eight American adults taking the pills or injectables now, big employers from Cigna to PricewaterhouseCoopers are dropping coverage of so-called GLP-1s in droves. Others, like Chevron, are making workers jump through extra hoops to get coverage—and to ensure the drugs are used effectively—such as requiring multiple weigh-ins a month, meal-tracking on apps or sessions with an online health coach. 
  • “More than a quarter of big companies say they are adding criteria this year or next, while 11% have dropped or are planning to drop coverage for weight-loss purposes altogether, according to soon-to-be released data from benefits-advisory firm Mercer.”
• and
  • “A columnist wore an Oura Ring 5, Google Fitbit Air, Whoop MG, and Apple Watch Series 11 for three weeks to compare their performance.
  • “Sleep tracking was tested against a polysomnogram in a sleep study; the Apple Watch and Fitbit Air showed the most accurate sleep duration.
  • “Heart-rate tracking was compared against a chest strap. Oura and Whoop offer detailed data but require subscriptions.” * * *
  • “Oura requires a $6-a-month subscription. Stop paying and it locks up your biometrics, leaving you with basic three-score feedback (sleep, readiness and activity). Whoop doesn’t charge an upfront hardware cost but there’s a mandatory membership starting at $199 a year. And the accessories—bra, shorts, etc.—aren’t cheap.
  • “That still isn’t a lot to pay if you can get off the couch and build lasting change. But if you want data without a monthly fee, the pricier Apple Watch will provide it. And you can skip the Google Health $10-a-month premium plan and still use the Fitbit. 
  • “Living a healthy life is easy in theory but hard in practice. I welcome wearables steering me toward good choices, and decided the Oura Ring plus an Apple Watch is still the best combo for me. After a decade and a half of tracking my fitness, I’ve settled on using these devices to identify long-term trends and help me build better habits. Yet no matter how smart and capable they’ve become, they still can’t replace my own body’s intuition.”